COMMUNIQUÉS West-GlobeNewswire

MaxCyte to Participate in Three Upcoming Investor Conferences
28/10/2026
ROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of [...]
BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026
28/10/2026
BURLINGTON, Mass. and JERUSALEM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments for mental [...]
ProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming Conferences
28/10/2026
ProQR to present its ADAR-mediated RNA editing approach and progress toward next-generation editing oligonucleotides at TIDES Europe plenary session AX-0810 Phase 1 data to be featured in two poster presentations at [...]
Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues
28/10/2026
– Patent provides coverage into 2043 for key aspects of how Symvess is manufactured, sterilized, stored and shipped. DURHAM, N.C., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage [...]
Curabotics Enters National Contract with Capstone Health Alliance, Bringing Robotics and Automation to Hundreds of Hospitals
28/10/2026
Unique agreement gives Capstone's member network direct access to Curabotics' proven automation solutions JACKSONVILLE, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Curabotics , a healthcare technology company dedicated to [...]
Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
28/10/2026
FOSTER CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase 3 IMpactMF trial [...]
Newron Pharmaceuticals to Participate in November Investor Conferences
28/10/2026
MILAN and MORRISTOWN, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with [...]
Scipher Medicine Launches PrismTcell™, the Next Molecular Treatment Response Signature, for Abatacept in Rheumatoid Arthritis
28/10/2026
Clinical validation study with PrismTcell use achieved approximately 2-fold higher ACR50 response rate to abatacept. DURHAM, N.C., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Scipher Medicine (Scipher), a leader in immunology [...]
Neumarker Enter Collaboration to Advance Precision Medicine in Depression
28/10/2026
Collaboration aims to leverage AI-native brain intelligence to predict treatment response and enable more personalized depression care MOUNTAIN VIEW, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Neumarker, Inc., an AI- [...]
TCG Labs Soleil Highlights Portfolio Momentum with Three Programs Entering First-in-Human Clinical Trials Across Oncology and Cardiovascular Disease
28/10/2026
Fourth program advancing toward the clinic in respiratory disease with additional candidates progressing across areas of significant unmet need, further underscoring the productivity of TCG Labs Soleil’s in-house R& [...]
INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement
28/10/2026
BOCA RATON, Fla., Oct. 28, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a [...]
UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
28/10/2026
Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTO Results demonstrate sustained disease control through extended follow-up among [...]
ORYZON to participate in upcoming events in November
28/10/2026
MADRID and CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its [...]
Noom Study Finds Members Further Along in Its GLP-1Rx Program Report Higher “Flourishing” and “Quality of Life”
28/10/2026
Analysis of 1,259 members of Noom’s GLP-1Rx Program finds clinically meaningful differences in anxiety, depression, fatigue, pain, cognition, social participation and overall health-related quality of life at Day 145 [...]
Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial
28/10/2026
BRISBANE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)
28/10/2026
Submission backed by clinical data from two clinical studies representing 168 subjects demonstrating quality of life improvements and an approximately 40% reduction in neuropathic pain scores in the active treatment [...]
Sofwave to Participate in Upcoming November Investor Conferences
28/10/2026
SAN CLEMENTE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today [...]
Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells
28/10/2026
Findings provide new insight into simufilam’s effects on cellular stress responses and mitochondrial function New research demonstrates a 37% reduction in elevated ATF4, consistent with attenuation of the ATF4- [...]
Immutep Receives A$2.16 million French R&D Tax Incentive
28/10/2026
SYDNEY, AUSTRALIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today [...]

Pages